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Abstract
A safe, efficacious vaccine is required to stop the AIDS pandemic. Disappointing results from the STEP trial implied a need to
include humoral anti-HIV-1 responses, a notion supported by RV144 trial data even though correlates of protection are
unknown. We vaccinated rhesus macaques with recombinant simian immunodeficiency virus (SIV) Gag-Pol particles, HIV-1
Tat and trimeric clade C (HIV-C) gp160, which induced cross-neutralizing antibodies (nAbs) and robust cellular immune
responses. After five low-dose mucosal challenges with a simian-human immunodeficiency virus (SHIV) that encoded a
heterologous R5 HIV-C envelope (22.1% divergence from the gp160 immunogen), 94% of controls became viremic, whereas
one third of vaccinees remained virus-free. Upon high-dose SHIV rechallenge, all controls became infected, whereas some
vaccinees remained aviremic. Peak viremia was inversely correlated with both cellular immunity (p,0.001) and cross-nAb
titers (p,0.001). These data simultaneously linked cellular as well as humoral immune responses with the degree of
protection for the first time.
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Introduction
According to recent UNAIDS estimates (www.UNAIDS.org),
approximately 34 million people are infected with HIV; of these,
,56% harbor HIV-1 clade C (HIV-C). Extensive efforts have
focused on developing AIDS vaccines. Disappointing results from
the STEP trial, which sought to induce cellular immunity, point to
the need to induce balanced virus-specific immunity, including
humoral responses [1,2]. Data from the recent RV144 Phase III
Thai trial support this concept and showed that separate
immunogens, each designed to individually induce either anti-
body-based or cell-based HIV-specific immunity, conferred some
protection (31.2%) when used in combination [3].
Due to the lack of natural protective immunity against HIV,
correlates of protection can be defined only in the context of at
least partially effective vaccines [4]. Defining correlates of
protection would allow rational improvements in candidate
vaccines and immunization protocols. Since RV144 is the only
HIV-1 vaccine trial that has shown partial efficacy, extensive
efforts are underway to define correlates of protection using
samples collected during this trial [5]; to date, however, no definite
correlates have been identified. In this context, information gained
from biologically relevant animal models where vaccinees have
resisted immunodeficiency virus challenges can serve as a source of
information to define potential correlates of protection against
HIV-1.
Simian immunodeficiency virus (SIV)-infected rhesus macaques
(RM) develop a disease spectrum similar to HIV-infected humans,
and consequently, the SIV/RM model has been used to test the
efficacy of AIDS vaccine candidates. However, SIV Env differs
substantially from HIV-1 Env and thus, recombinant simian-
human immunodeficiency viruses (SHIVs) have been derived that
encode HIV-1 envelopes, the target of neutralizing antibody (nAb)
responses. SHIVs thus allow assessing the protective role of anti-
HIV-1 nAb responses in vivo. The first-generation of SHIV
strains, however, reflected neither the biology of transmitted HIV-
1 nor the early events in host infection observed during acute
HIV-1 infection in humans. One of the earlier SHIVs,
SHIV89.6P, encodes a dual-tropic primary HIV-1 envelope that
exhibits CXCR4 tropism in vivo and irreversibly destroys the CD4
T-cell population within 2 weeks; most RM fail to seroconvert due
to this acute pathogenicity [6]. The latter was linked to the
preference of SHIV89.6P for naı ¨ve T cells [7]. In contrast, acutely
transmitted HIV-1 almost always has exclusive CCR5 coreceptor
usage and targets the memory CD4 T-cell population. Of note, R5
tropism is observed in almost all HIV-1 transmission events linked
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22010to mucosal exposure, which is the dominant mode (,90%) of all
HIV-1 acquisitions (reviewed in [8]). Ideally, a biologically
relevant SHIV challenge strain used to assess the efficacy of
candidate AIDS vaccines should reflect the nature of newly
acquired HIV-1 in humans, including R5 tropism and gradual
disease progression [9].
In order to develop biologically relevant challenge viruses, we
constructed a series of novel SHIVs [10,11,12] that are exclusively
CCR5 tropic and cause gradual disease progression [13,14]. These
SHIVs encode HIV-C envelopes and offer the advantage of
reflecting the world’s most prevalent HIV-1 subtype. One of these
constructs, SHIV-1157ipEL-p [12] encodes env of HIV1157i, an
R5 HIV-C isolated from a relatively recently infected Zambian
infant. The SHIV backbone was derived from SHIV-1157ipd3N4
[10], originally built from SIVmac239 but engineered to contain
additional NF-kB sites in the long-terminal repeats (LTRs) to
boost virus replication. HIV-C strains generally have additional
NF-kB sites in their LTRs [15] and thus, SHIV-1157ipd3N4 and
SHIVs based upon its backbone represent this unique HIV-C
feature. Both SHIV-1157ipd3N4 and SHIV-1157ip (a variant
containing the same env as SHIV-1157ipEL-p) have caused AIDS
in RM [13,14]. Considering these features, i.e., exclusive R5
tropism of an envelope derived from a recently acquired HIV-C
plus the fact the both components used to build the new SHIV-
1157ipEL-p chimera had pathogenic potential, we used the latter
as challenge virus.
To better reflect the biology of HIV-1 transmission among
humans, we modified the virus challenge regimen; instead of
challenging vaccinated RM with a single, high-dose of virus, we
used five weekly lower-dose intrarectal (i.r.) SHIV challenges in an
attempt to approximate the relatively low inocula thought to be
involved in mucosal HIV-1 exposures. Importantly, primate
challenge studies should employ viruses that are heterologous to
those used for vaccine preparation since human vaccinees are
unlikely to be exposed to HIV-1 strains exactly matching the
vaccines [9]. To fulfill these conditions, we mismatched the HIV-
C Env immunogen with the envelope carried by SHIV-1157ipEL-
p.
Several viral and bacterial vectors that encode HIV-1 proteins
have been tested in animal studies as well as in human clinical
trials. The latter have shown that preexisting anti-vector immunity
is a major concern regarding the immunogenicity of novel vaccine
vectors [16,17]. Some vectors may potentially enhance host
susceptibility to HIV-1 infection via immune activation, e.g.,
homing of activated CD4
+ T cells to mucosal sites [18], or
activation of dendritic cell (DC)/T-cell interactions [19]. The
potential of integration into the host cell genome is also a concern
for some viral vectors.
We explored a recombinant protein-only immunization ap-
proach to bypass such concerns. This would induce strong
humoral and CD4
+ T-cell responses; CD8
+ T-cell responses can
also be expected due to antigen cross-presentation. To note, a
human DC subset that efficiently cross-presents soluble proteins
(equivalent to mouse CD8
+ DC) has been recently reported by
independent investigators (reviewed in [20]). Macaques were
immunized with SIV Gag-Pol particles derived from SIVmac239
or SIVmne (homologous or partially heterologous to the challenge
SHIV, respectively), multimeric HIV-C gp160 and HIV-1 Tat.
Importantly, the gp160 immunogen was derived from HIV1084i
[21], a recently transmitted HIV-C with an env gene that was
phylogenetically distinct from SHIV-1157ipEL-p env. Vaccination
induced cellular as well as humoral immunity – at high levels in
some vaccinees, which were completely protected from viremia.
We found a highly significant correlation between the responses
induced by both arms of the immune system and the degree of
protection.
Results
Vaccine safety and immunogenicity
Two sets of RM were immunized three times with multimeric
HIV-C gp160 (from strain HIV1084i), HIV-1 Tat, and either
SIVmne-derived (Group 1) or SIVmac239-derived (Group 2) Gag-
Pol particles in incomplete Freund’s adjuvant (IFA). The controls
(Group 3) received IFA alone (Figure 1A). The Env immunogen
was 22.1% divergent from Env of the challenge virus; the two Envs
were clearly distinct by phylogenetic analysis (Figure 1B). The
SIVmne-derived Gag-Pol particles given to Group 1 vaccinees
were partially heterologous (5.5% divergent) to Gag-Pol of the
challenge virus (Figure S1).
None of the vaccine recipients developed any untoward side
effects. No local reactogenicity was noted.
Virus-specific immune responses measured on the day of
challenge (two weeks after last vaccination) are shown in
Figures 2 and 3. All vaccinees (Groups 1+2) developed high-titer
binding antibodies to SIVmac251 Gag, HIV-1 Tat and HIV-C
gp120 (Figure 2A). Results of neutralization assays against various
R5 SHIV strains, including heterologous SHIV-1157ipEL-p [12],
SHIV-1157ipd3N4 [10], SHIV-2873Nip [11] and SHIVSF162P4,a
clade B strain [22], are shown in Figure 2B. All 12 vaccinees had
nAb responses against the challenge virus, SHIV-1157ipEL-p, by
peripheral blood mononuclear cell (PBMC)-based assay.
Two weeks after the last immunization, some vaccinees had
strong cellular immune responses to SIV Gag and/or HIV-1 Tat
as measured by interferon (IFN)-c ELISPOT (Figure 3A) and
intracellular cytokine staining (ICS) assays (Figure 3B). Three out
of 4 RM from Group 2 and one out of 12 RM from Group 1
showed strong ELISPOT- and ICS responses against SIV Gag
(Figure 3 A,B). This disparity may be due to the fact that
overlapping synthetic peptides used in those assays were of
SIVmac239 origin, which is homologous to the Gag-Pol particles
given to Group 2 but partially heterologous to those given to
Group 1. In some vaccinees (RRi-11, RTr-11, RGe-11), ELI-
SPOT responses were as strong as those induced by highly
immunogenic live vectors [23,24]. SIV Gag-specific responses
were seen in both CD4
+ and CD8
+ T cells, mostly with central
memory phenotypes, and a significant fraction of each cell
population displayed polyfunctional cytokine responses
(Figure 3B). Most vaccinees also had virus-specific proliferative
responses (Figure 3C).
Protection against mucosal challenges with
SHIV-1157ipEL-p
All vaccinated (Groups 1 and 2) and control RM (Group 3 plus
Group 4, as a part of another study) were given five i.r. low-dose
SHIV-1157ipEL-p challenges (8000 50% tissue culture infectious
doses (TCID50) measured by TZM-bl assay) (Figure 1). Env of the
challenge virus was heterologous to the HIV1084i gp160
immunogen (22.1% divergent) (Figure 1B), whereas the challenge
virus Gag was partially heterologous to the Gag-Pol particles given
to Group 1 (Figure S1). Three weeks after the final low-dose virus
exposure, 94% of all controls (Groups 3+4) were infected,
compared to 67% of all vaccinees (P=0.07 by Fisher’s exact test
(one-sided)); monkeys RFo-11, RGe-11, RRi-11 and RTr-11
remained aviremic (Figure 4A–D). The vaccinees’ mean peak
plasma viral RNA (vRNA) load was significantly lower than the
combined controls’ (6.6610
5 versus 2.8610
6 copies/ml; P=0.045,
Wilcoxon rank-sum test (for statistical analysis, aviremic RM were
Correlates of Protection against Clade C SHIV
PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22010Figure 1. Experimental time line and phylogenetic analysis of Env of immunogen and challenge virus. (A) Experimental design. Groups
1 and 2 were vaccinated with HIV-1 Tat, HIV1084i gp160, and Gag-Pol particles from either SIVmne (Group 1) or SIVmac239 (Group 2; 100 mg of each
immunogen i.m. in incomplete Freund’s adjuvant (IFA)); Group 3 controls received IFA alone. Maximally 5 weekly low-dose i.r. challenges of SHIV-
1157ipEL-p were given (8,000 50% tissue culture infectious doses (TCID50, measured by TZM-bl assay). SHIV-1157ipEL-p is heterologous to HIV1084i
Env and SIVmne Gag-Pol immunogens. Group 4, unvaccinated rhesus monkeys (RM) challenged identically with the same virus stock as part of other
studies. All RM with no viremia at week 7 (shown in red) were rechallenged i.r. with a single high-dose of SHIV-1157ipEL-p (1.5610
5 TCID50; red
arrows). Group 5: naı ¨ve controls for the high-dose challenge. *, Mamu A*001-positive RM. (B) Phylogenetic analysis of Env sequences of immunogen
and challenge virus. HIV-1 Env sequences of clade C and non-clade C reference strains were obtained from the Los Alamos HIV-1 sequence database.
The evolutionary tree was inferred using the Neighbor-Joining method [47] by MEGA4 software [48]. The immunogen and challenge virus sequences
were on different branches within cluster of HIV-C Env sequences.
doi:10.1371/journal.pone.0022010.g001
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PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22010assigned a vRNA load of 49 copies/ml, based upon an assay
sensitivity of 50 copies/ml [25]). Likewise, the mean 7-week ‘‘area
under the curve’’ viral loads differed significantly between the
vaccinees and controls (P=0.01). The combined vaccinees of
Groups 1+2 also had significant delays in both time until first
detectable viremia (Figure 4E) and time until peak viremia
(Figure 4F) compared to the combined Groups 3+4 controls.
Significant delays of both parameters were also observed when
Figure 2. Humoral immunity at the time of initial low-dose SHIV-1157ipEL-p challenge. (A) Reciprocal serum antibody ELISA titers against
SIVmac251 p27 Gag, HIV-1 Tat and heterologous clade C HIVCN54 gp120. (B) NAb activity SHIV-1157ipEL-p and, SHIVSF162P4) and Tier 2 (SHIV-
1157ipd3N4, SHIV-2873Nip) viruses was measured in human PBMC in the presence of polymyxin B. TZM-bl neutralization assay was also performed
against SHIV-1157ipEL-p. IC50 and IC90 titers, reciprocal dilutions of serum giving 50% and 90% neutralization (inhibitory concentrations), respectively,
are shown. *, Mamu A*001-positive RM.
doi:10.1371/journal.pone.0022010.g002
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(Figure S2).
Because one control remained virus-negative, all RM without
evidence of viremia after five low-dose challenges (shown in red,
Figure 1) were rechallenged once i.r. at week 7 with a high dose of
SHIV-1157ipEL-p (1.5610
5 TCID50); these included two mon-
keys each from Groups 1 and 2 and one from Group 3 (shown in
red in Figure 1A). By 2 weeks post-rechallenge, peak vRNA loads
of .10
6 copies/ml plasma were observed in RAk-11 (a control
RM of Group 3) plus four identically challenged newly-enrolled
naı ¨ve RM (Figure 4G). In contrast, two out of the four vaccinees
(RRi-11 and RTr-11) remained virus-negative and one, RGe-11,
showed only two transient blips of ,10
4 vRNA copies/ml
(Figure 4H). No virus was detected ever in RRi-11 and RTr-11
Figure 3. Cellular immunity at the time of initial low-dose SHIV-1157ipEL-p challenge. (A) The frequency of antigen-specific cells
measured by IFN-c ELISPOT assay. No responses were seen in control Group 3. (B) The frequency of SIV Gag and HIV-1 Tat-specific peripheral blood
CD4
+ and CD8
+ T cells producing intracellular IFN-c, IL-2 and TNF-a was measured using multiparameter flow cytometry. (C) Proliferation of
peripheral blood CD4
+ and CD8
+ T cells in response to SIV Gag or HIV-1 Tat proteins. *, Mamu A*001-positive RM.
doi:10.1371/journal.pone.0022010.g003
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PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e22010Figure 4. Plasma viral RNA (vRNA) loads after SHIV-1157ipEL-p challenges and Kaplan-Meier plots. (A–D)vRNA loadsafterlow-doseviral
challenges for Groups 1-4. Black symbols, vRNA loads of Groups 1-4 during the weekly low-dose challenges (blue arrows); red symbols, vRNA loads of
animals later given high-dose challenge (red arrows; see also Figure 1 legend). (E) Kaplan-Meier plots depicting the fraction of monkeys remaining
aviremic. (F) Kaplan-Meier plots depicting the fraction of animals not yet having reached peak viremia. (G–H) vRNA loads after a single high-dose SHIV-
1157ipEL-p challenge of newly recruited naı ¨ve controls (Group 5) plus prior control monkey RAk-11 (G), or rechallenge of vaccinees (H). Probability (P)
values were determined by 2-sided log-rank analysis. Horizontal dashed lines in A–D, G–H: limit of RT-PCR assay detection (50 vRNA copies/ml; [25]).
doi:10.1371/journal.pone.0022010.g004
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shown) or ultracentrifuged plasma taken at week 4 post-
rechallenge (Table S1). Importantly, PBMC from RRi-11, RTr-
11 and RGe-11 supported SHIV-1157ipEL-p replication in vitro
but only after depletion of CD8
+ T cells (Figure S3). Thus, the
combined data suggest that vaccination completely prevented
viremia in two RM and prevented persistent, systemic infection in
a third. Three additional monkeys had evidence of viral
containment with plasma viral loads $1 log lower than the mean
plasma vRNA load of all 17 controls of Groups 3+4. Lowering of
peak viremia by $1 log has been previously used as a measure of
relative vaccine-induced viral containment [26,27]. By this
measure, our vaccine strategy provided 50% complete or partial
protection.
Correlates of protection
Next, we sought to correlate vaccine-induced nAb and/or
cellular immune responses, measured at week 0 (day of 1
st virus
exposure), with viral load parameters following completion of all
viral challenges, including high-dose rechallenge. Vaccinees were
ranked according to increasing peak vRNA loads (Figure 5);
aviremic monkeys (RRi-11 and RTr-11) were assigned vRNA
loads of 49 copies/ml (assay sensitivity, 50 copies/ml).
All 12 vaccinees had nAb responses against the challenge virus,
SHIV-1157ipEL-p, as measured by PBMC-based assay (Figure 2B
and 5A) whereas 11 out of 12 had nAb responses by TZM-bl assay
(Figure 5B). NAb titers measured as 90% inhibitory concentration
(IC90) by PBMC assay as well as 50% inhibitory concentration
(IC50) measured by TZM-bl assay showed a strong inverse
correlation (P,0.001) with peak plasma viremia (Figure 5A, 5B).
Similarly, cellular immunity, as measured by combined IFN-c
ELISPOT activity against SIV Gag and HIV-1 Tat, also showed a
highly significant inverse correlation (P,0.001) with peak vRNA
loads (Figure 5C). Thus, both humoral and cellular immune
responses were significant correlates of protection. To our
knowledge, this is the first report that simultaneously linked nAb
titers and antiviral cellular immunity with the degree of protection.
Furthermore, the cellular immune responses in RM with complete
or partial protection were polyfunctional as shown by intracellular
production of IFN-c, IL-2 and TNFa after stimulation with SIV
Gag and HIV-1 Tat peptides (Figure 3B and 5D).
On the day of high-dose rechallenge (week 7), just prior to virus
re-exposure, the SHIV-specific cellular responses had significantly
declined compared to week 0 values in three out of the four
vaccinees (RRi-11, RTr-11, RGe-11) that had remained aviremic
after the initial five low-dose virus exposures (Figure 6A, 6B). We
ascribe this lack of anamnestic responses to these monkeys
remaining uninfected, either because of an insufficient virus dose
or immune protection. The fourth monkey, RFo-11, had no
detectable cytokine production at either week 0 or 7 and was
infected after the single-high dose exposure.
Next, we assessed nAb responses on the days of 1
st low-dose and
the one-time high-dose SHIV challenges in the context of the final
outcomes for the four vaccinees that had remained aviremic after
the five low-dose challenges. While the pattern of nAb titers
between weeks 0 and 7 varied, it is important to note that the two
RM that remained aviremic after all SHIV challenges had nAb
titers $600 against the challenge virus (measured as IC50 by
TZM-bl assay) (Figure 6C).
Assessment of different degrees of protection
Two RM remained completely aviremic despite all virus
challenges (RRi-11 and RTr-11). We sought to test whether
sterilizing immunity was achieved or whether cryptic infection
resulting in viral tissue reservoirs may have occurred despite a lack
of measurable plasma viremia at any time point. As mentioned
above, post-challenge LN biopsies failed to reveal any viral
sequences. While we considered ablating CD8
+ cells with a
cytotoxic monoclonal antibody to allow virus to emerge from
tissue reservoirs during a transient loss of virus-specific CD8
+ T
and NK cells, the high nAb levels in the two protected monkeys
may likely have prevented viremia. Likewise, the presence of high
nAb titers precluded using blood transfer to naı ¨ve RM to test for
infectious virus. Thus, we chose an alternate strategy to examine
the possibility of cryptic infection and our analysis focused on: 1)
the generation of new antiviral immune responses against viral
targets absent from our vaccine, e.g. Nef, and 2) cryptic infection,
as defined by boosting of preexisting cellular antiviral immune
responses. The latter implies presentation of viral peptides through
MHC class I molecules occurred after at least a few target cells
became productively infected.
Parameters defining different degrees of protection following
viral exposures are summarized in Figure 7A. The distribution of
peak vRNA loads for all controls and vaccinees along with a
schema of the different protection levels are shown in Figure 7B.
Remarkably, monkey RRi-11 fulfilled all criteria for sterilizing
immunity (Figure 7C). Cellular immunity measured by SIV Gag-
and HIV-1 Tat-specific ELISPOTs were very high after
vaccination (.3,500 combined SFU/10
6 PBMC). At the time of
high-dose rechallenge, these responses had dropped to ,200
SFU/10
6 PBMC and remained low even after rechallenge
(Figure 7C, left panel). ICS also showed no anamnestic cellular
responses (Figure 7C, right panel). In contrast, monkey RTr-11
had a clear anamnestic cellular immune response at 4 weeks post-
high-dose virus challenge (week 11; Figure 7D), even though the
RM was never viremic and no viral sequences were found in LN
tissue. A third animal, RGe-11, only had two low-level blips of
viremia, but negative LN biopsies. Anamnestic cellular immune
responses were clearly seen at week 11 in this RM (Figure 7E),
which also mounted novel cellular responses against Nef.
Discussion
After all virus challenges, we achieved 50% protection overall,
combining cases of partial protection (i.e., $1 log lower peak
viremia compared to the controls, the same parameter used in
earlier studies [26,27]), protection from persistent systemic viremia
(i.e., only transient viremia or cryptic infection), and sterilizing
immunity. Our data give proof-of-concept that a high degree of
protection can be achieved with a vaccine strategy designed to
recruit cellular as well as humoral immune defenses. To our
knowledge, vaccine protection against a challenge virus carrying a
completely mismatched HIV-C envelope has been linked for the
first time to the simultaneous induction of cellular as well as nAb
responses with a high degree of significance.
The two envelopes used to generate either the gp160
immunogen or the challenge R5 clade C SHIV were derived
from distinct HIV-C strains (HIV1084i and HIV1157i, respec-
tively), and the 22% amino acid divergence between the two
envelopes is representative of intra-community sequence variabil-
ity since both HIV-C strains were isolated from infected infants in
Lusaka, Zambia [12,21]. Thus, our model was as true-to-life as
possible for approximating HIV-1 exposure among humans
exposed to locally circulating virus strains.
Our multiple low-dose, mucosal R5 SHIV challenge model was
also designed to better reflect the relatively low infectious inocula,
which are thought to be involved during mucosal HIV-1 exposure
of humans [28], rather than the single high-dose challenges used in
Correlates of Protection against Clade C SHIV
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22010Figure 5. Immune parameters associated with protection. Vaccinees were ranked in ascending order of peak viremia after all virus challenges
(animals that received the high-dose challenge are shown in red), and immune parameters measured on the day of 1
st low-dose virus challenge are
presented. W, week of peak viremia. (A) Neutralizing antibody titer (IC50) measured by TZM-bl cell-based assay vs. peak plasma vRNA. (B) Neutralizing
antibody titer (IC90) measured by PBMC-based assay vs. peak plasma vRNA. (C). SIV Gag- plus HIV-1 Tat-specific IFN-c ELISPOTs vs. peak plasma vRNA.
(D) SIV Gag- plus HIV-1 Tat-specific CD4
+ and CD8
+ T cells producing IL-2, IFN-c and TNF-a vs. peak plasma vRNA. Inverse correlations of peak vRNA
with cellular (P,0.001) and nAb (P,0.001) responses were determined by Spearman analyses. The mean peak plasma viremia of all controls is shown
by the X mark. All control animals were tested in neutralization (TZM-bl, PBMC) and ELISPOT assays; one control animal was included in the ICS assays.
doi:10.1371/journal.pone.0022010.g005
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PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e22010earlier primate studies. The control animal (RAk-11) that
remained aviremic during the low-dose challenge phase can be
considered as representative of an uneventful mucosal virus
exposure. The same can be said about the vaccinee RFo-11 that
had remained virus-free after the low-dose challenges but
promptly became highly viremic after high-dose challenge. This
Figure 6. Immune responses on the day of high-dose virus challenge. Cellular and nAb responses at week 0 (day of first virus exposure) and
week 7 (day of high-dose virus challenge) for: (A) SIV Gag- and HIV-1 Tat-specific IFN-c ELISPOT responses. (B) SIV Gag and HIV-1 Tat-specific
peripheral blood CD4
+ and CD8
+ T cells producing intracellular IFN-c, IL-2 & TNF-a (measured by multiparameter flow cytometry). (C) nAb titers
against the challenge virus (IC50 measured by TZM-bl assay).
doi:10.1371/journal.pone.0022010.g006
Correlates of Protection against Clade C SHIV
PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e22010RM had failed to mount significant ELISPOT and ICS responses
and had only relatively low nAb titers after the completion of the
vaccine regimen. Our experimental design allowed a separate
statistical analysis of the low-dose challenge phase while the
subsequent one-time high-dose challenge permitted us to differ-
entiate between insufficient virus challenge dose and vaccine
effects. Overall, we observed substantial vaccine efficacy during
the low-dose challenge phase. Out of 17 control RM, 16 became
viremic (94%), in contrast to a 67% infection rate among all 12
vaccinees. The vaccinees had significant delays in first-detectable
viremia, lower peak vRNA loads and area-under-the curve values
compared to the controls.
To our knowledge, this is the first study to test the
immunogenicity and efficacy of multimeric gp160 from a recently
transmitted HIV-C against multiple low-dose challenges with an
R5 SHIV that also encoded a recently transmitted envelope from
a distinct viral isolate. Emerging data indicate that the configu-
ration of the HIV-C envelope from recently transmitted viruses
Figure 7. Degrees of protection. (A) Parameters to define different degrees of protection. Transient viremia, vRNA blip(s) (,10
4 vRNA copies/ml,
which is not expected to result in seroconversion); viral containment, lowering of peak vRNA by $1 log vs. controls. Anti-Nef (non-vaccine
component) responses were measured to detect neo-antigen reactivity. The fold increase in ELISPOTs after high-dose virus challenge compared to
the day of high-dose virus challenge was determined to identify anamnestic cellular immune responses. (B) Distribution of peak vRNA. Red lines,
means; dashed lines: upper, viremia 1 log lower than mean of controls; middle, 1610
4 vRNA copies/ml; lower, limit of vRNA detection (50 copies/ml).
(C–E) Anamnestic cellular responses and neo-antigen reactivity in the monkeys indicated. Left panels, IFN-c ELISPOTs against SIV Gag (open bars) and
Nef (striped bars, neo-antigen). Right panels, SIV Gag-specific intracellular cytokine staining.
doi:10.1371/journal.pone.0022010.g007
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context of HIV-1 infection, clade C Envs are also more
immunogenic and more likely to induce cross-neutralizing Abs
than HIV-1 clade B Envs [31]. Our induction of strong nAb
responses against heterologous SHIV-C (SHIV-1157ipEL-p) and
detectable neutralization of heterologous viruses (SHIV-
1157ipd3N4 and SHIV-2873Nip) warrant the use of Env
immunogens derived from recently transmitted HIV-C strains.
Oligomeric gp140 or gp160 immunogens have been tested in
macaques; generally, nAb breadth was somewhat limited [32].
Immunization of macaques with V2-deleted SF162 gp140 trimers
induced nAbs and protected 12 out of 12 monkeys against mucosal
challenge with SHIVSF162P4 [33]; however, the challenge virus
exactly matched the immunogen and thus is not reflective of a
real-life situation, in which human AIDS vaccine recipients will be
exposed to HIV-1 strains that do not match their vaccine. Here we
report protection against a challenge virus with 22.1% Env
divergence from the immunogen.
We performed our immunizations by the intramuscular (i.m)
route. For HIV-1 Env protein immunization, the i.m route was
described as more immunogenic compared to the mucosal route
[33]. In that study, i.m. immunized monkeys were protected
against homologous clade B SHIV challenge but not those
immunized only mucosally.
Non-human primate model studies involving R5 SHIV
challenges may be used to obtain information about a critical
parameter in AIDS vaccine development: the nAb titer that needs
to be achieved to protect against systemic infection. The issue of
which nAb assay to employ for immunogenicity screening is
currently under intense study. Our data show that nAb titers vary
significantly depending on the assay system used, including target
cells. The PBMC assay-based IC90 values for monkeys RRi-11 and
RTr-11 (vaccinees that never showed viremia) on the day of first
virus exposure were .1000. In contrast, the TZM-bl assay yielded
IC50 values in the range of 200 to 300. The fact that TZM-bl
assay-derived nAb titers were significantly lower is in agreement
with findings of others [34,35]. Nonetheless, the overall rank order
of anti-SHIV-1157ipEL-p nAb responses measured by the two
assays followed a similar although not identical pattern and both
assays ranked RRi-11 and RTr-11 at the top among all vaccinees.
Although our functional assays of humoral immunity focused on
neutralizing activity, other antibody effector functions could have
contributed to the overall vaccine efficacy in our study, such as
antibody-dependent cellular cytotoxicity (ADCC) and antibody-
dependent cell-mediated viral inhibition (ADCVI) [36,37].
Analysis of such additional antibody effector functions in our
study is complicated by the very high challenge virus-specific
neutralizing activity shown by the protected vaccinees.
A recent study reported antibody-mediated transcytosis inhibi-
tion of SHIV89.6P across the epithelial layer [38] with non-
neutralizing polyclonal antibodies. Inhibition of transcytosis in the
complete absence of standard neutralizing activity was described
as the protective mechanism [39]. Lastly, multimeric IgM and IgA
antibodies can aggregate virions and inhibit movement through
mucosa and epithelial layers [40]. Inhibition of virus penetration
through mucosal barriers may be achieved by such antiviral
antibody functions that differ from standard neutralization and
may also be beneficial.
Recombinant protein immunization induced both humoral and
cellular immunity that included both CD4 as well as CD8 T-cell
responses and is in agreement with data of others [41]. We also
noted that the protected RM in our study mounted virus-specific
polyfunctional cellular immune responses while such responses
were either low or undetectable among unprotected vaccinees.
These results support the notion that polyfunctional T cells can
provide a better degree of protection [42,43].
It has been widely discussed that for protection against mucosal
virus challenges, immune responses in mucosal compartments are
highly desired. However, we had to refrain from performing rectal
biopsies in order to maintain mucosal integrity during the multiple
low-dose SHIV-C challenges.
During the follow-up time of our study, post-acute viremia did
not differ between infected vaccinees and controls. Interestingly,
this parallels the results of the RV144 trial, as there was no
significant difference in mean viral loads between vaccinees with
HIV-1 infection compared to infected individuals in the placebo
group [3]. Remarkably, in our primate study, one third of all
vaccinees remained aviremic throughout the initial low-dose
challenge phase. While these data are encouraging, the task will
be to improve the potency of the cellular immunity against
heterologous viruses and to develop immunogens capable of
generating nAb responses with increased breadth to not only
neutralize viruses circulating within the same local community, but
also more divergent HIV-C isolates as well as HIV-1 strains of
different clades. Our study provides evidence for the importance of
generating balanced cellular and humoral immune responses by
candidate AIDS vaccines.
Methods
Animals
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Animals of the U.S. Public Health Services/National Institutes of
Health, as well as according to the recommendations in the Weatherall
report on ‘‘The Use of Non-human Primates in Research’’ (http://
www.acmedsci.ac.uk/images/project/nhpdownl.pdf). The protocol
was approved by the Committee on the Ethics of Animal Experiments
of Emory University (IACUC ID: 261-2008Y; Emory University
Animal Welfare Assurance Number A3180-01). The rhesus monkeys
were housed at the Yerkes National Primate Research Center
(YNPRC, Emory University, Atlanta, GA). YNPRC facilities are fully
accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care International. Animal experiments were
approved by the Institutional Animal Care and Use Committees at
Emory and the Dana-Farber Cancer Institute. All animal procedures
were performed under ketamine-telazol anesthesia. Because the
experiments described here involved a virus that may cause an
incurable disease, such as AIDS, discomfort, stress and pain may occur.
Animals were closely monitored and observed for development of
disease at least twice daily. If the animals are determined to be under
stress or in discomfort, appropriate anesthetics and/or analgesics are
administered as directed by the clinical veterinary staff. Euthanasia is
also an option should treatment not alleviate stress. In the current
study, no untoward clinical problems were noted, and none of the
virus-infected monkeys progressed to AIDS.
All animals were Mamu B*008 and B*017 negative; Mamu
A*001
+ RM are indicated in all Figures by an asterisk (*).
Viruses
HIV1084i [21] was isolated from a Zambian infant and was
used for the preparation of multimeric gp160 immunogen. The
challenge virus, SHIV-1157ipEL-p, was generated as described
earlier [12]. An animal-titrated stock of SHIV-1157ipEL-p was
prepared using Con A-stimulated RM PBMC cultured in the
presence of TNF-a (10 ng/ml). For low- and high-dose SHIV-
1157ipEL-p challenges, inocula of 8,000 TCID50 and 1.5610
5
TCID50 (titrated on TZM-bl cells) were used, respectively.
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HIV-1 Tat was purchased from Advanced Bioscience Labora-
tories, Inc. (Kensington, MD). SIVmac239 Gag-Pol particles,
SIVmne Gag-Pol particles and multimeric HIV1084i gp160 were
produced from recombinant vaccinia virus-infected BSC-40 cells
[44,45]. For each immunization, 100 mg of each protein in
incomplete Freund’s adjuvant (IFA) was administered i.m.
Measurement of plasma vRNA
Plasma vRNA was isolated by QiaAmp Viral RNA Mini-Kit
(Qiagen, Germantown, MD); vRNA levels were measured by
quantitative reverse-transcriptase polymerase chain reaction (RT-
PCR) for SIV gag sequences [25]. Additionally, primers/probes
according to Lifson were used [46]. Assay sensitivity was 50 vRNA
copies/ml [25].
Interferon-c ELISPOT assay
Multiscreen-IP plates (Millipore, Billerica, MA) were coated
with anti-human IFN-c antibody (clone B27, BD Pharmingen,
San Jose, CA), blocked with 10% heat inactivated fetal bovine
serum (FBS) in RPMI-1640 (R-10). 1610
5 cells were incubated
overnight with SIVmac239 Gag or HIV-1 consensus B Tat
peptides (each peptide, 2 mg/ml) obtained through NIH AIDS
Research and Reference Reagent Program (ARRRP). The IFN-c-
secreting cells were detected by using biotinylated anti-human
IFN-c antibody (clone 7-B6-1, Mabtech, Cincinnati, OH),
Horseradish peroxidase-conjugated streptavidin (BD Biosciences,
San Jose, CA) and AEC chromogen substrate (BD Biosciences).
The spots were enumerated using an Immunospot ELISPOT
reader (CTL, Cleveland, OH). Assays were done in duplicates and
background counts with no peptide stimulation were subtracted.
Intracellular cytokine staining
PBMC were suspended in R-10 containing Brefeldin A (10 mg/
ml; Sigma-Aldrich, St. Louis, MO), Monensin (Golgistop, BD
Biosciences), anti-CD49d antibody (clone 9F10, BD Biosciences)
and anti-CD28-PECy7 antibody (clone CD28.2, eBioscience, San
Diego, CA). The cells were stimulated with SIVmac239 Gag or
HIV-1 Tat peptides at 37uC for 6 h. Cells were stained with anti-
CD3-AlexaFluor700 (clone SP34-2, BD-Pharmingen), anti-CD4-
PE (clone M-T477, BD-Pharmingen), anti-CD8-AmCyan (clone
SK1, BD-Biosciences) and anti-CD95-PE-Cy5 (clone DX2,
BioLegend, San Diego, CA) antibodies. The cells were then
fixed/permeabilized with Cytofix/Cytoperm (BD Pharmingen)
and stained intracellularly with anti-IL-2-APC (clone MQ1-
17H12, BD Pharmingen), anti-IFN-c-PerCP/Cy5.5 (clone 4S.B3,
BioLegend) and anti-TNF-a-PacificBlue (clone MAb11,
eBioscience) antibodies. At least 50,000 lymphocytes were
acquired on LSR-II, BD Immunocytometry Systems and data
was analyzed using FlowJo 6.0 (Tree Star, Inc., Ashland, OR)
software. Percentages of CD3
+CD4
+ and CD3
+CD8
+ cells
producing each of seven different possible combinations of IL-
2, IFN-c and TNF-a were determined. Background numbers of
cells producing cytokines without peptide stimulation were
subtracted.
Lymphocyte proliferation assay
PBMC were stained with CFSE (CellTrace
TM CFSE Cell
Proliferation Kit, Invitrogen, Camarillo, CA) and incubated with
or without antigen (SIV Gag, HIV-1 Tat; 2 mg/ml) for 5 days at
37uC. After incubation cells were stained with anti-CD3-Alexa
Fluor 700 (clone SP34-2), anti-CD4-PerCP (clone L200) and anti-
CD8-PE (clone RPA-T8) antibodies. The percentage of prolifer-
ating CD3
+CD4
+ and CD3
+CD8
+ cells was determined using
FACSDiva (BD Biosciences) software. Background proliferation
without any stimuli was subtracted.
Serum antibody binding titers
ELISA plates were coated with SIVmac251 p27 (Immunodiag-
nostics, Inc., Woburn, MA), HIV-1 Tat and HIVCN54 gp120
(ARRRP), diluted to 2 mg/ml. After blocking with 3% BSA, serial
serum dilutions were added in duplicate wells. Antibody binding
was detected by horseradish peroxidase conjugated rabbit anti-
monkey IgG (Sigma-Aldrich, St. Louis, MO) and O-Phenylene-
diamine dihydrochloride (OPD) + hydrogen peroxide substrate.
Titers were calculated as the greatest reciprocal serum dilution
giving OD readings .mean + 5 standard deviations above
background as measured using preimmune serum from the same
RM at the same dilution.
The HIV-CCN54 gp120 produced in insect cells was used to
measure anti-Env binding antibody titers. This ruled out the
possibility of detection of anti-vaccinia antibodies that might have
been induced due to vaccinia proteins possibly associated with our
immunogens that were produced by recombinant vaccinia
technology.
PBMC-based neutralization assay
Sera were tested against SHIV-1157ipEL-p, SHIV-2873Nip
and SHIVSF162P4 in PBMC-based neutralization assays, consid-
ered the gold-standard currently [35]. Predetermined virus inocula
were incubated with diluted sera in triplicate wells at 37uC for 1 h.
Virus was also incubated with medium alone (to determine 100%
virus production). After incubation, 5610
5 phytohemaglutinin
(PHA)-stimulated human PBMC were added to all wells in the
presence of IL-2 (40 U/ml) and polymyxin B (15 mg/ml). From
day 3 to 8, 100 ml/well of supernatant was collected and replaced
with medium. Supernatants were tested for SIV p27 by ELISA
(Advanced Bioscience Laboratories, Kensington, MD). The %
neutralization was determined for each serum sample as:
%neutralization=1002[(avg. p27 in wells containing virus+-
plasma mixture6100)/avg p27 in wells assigned for virus
production]. Pooled sera collected from naı ¨ve RM were used as
negative control, and a mixture of four broadly reactive nAbs (b12,
2F5, 4E10 and 2G12) served as positive control. Serum dilutions
that showed 50 and 90% inhibition of virus replication were
determined by logarithmic regression analysis.
TZM-bl cell-based neutralization assay
Sera collected from all monkeys on the day of the first low-dose
virus challenge were tested to determine nAb titers against the
challenge virus (SHIV-1157ipEL-p). Human PBMC-grown virus
was incubated with different serum dilutions and virus neutrali-
zation was determined by using the TZM-bl cell-based assay as
described [30].
Statistical analysis
Log-rank comparisons were used for time-to-infection and time-
to-peak viremia analyses between vaccinees vs. controls. Wilcoxon
rank sum test was used to compare continuous variables (peak
viremia and area-under-the-curve) between groups. Associations
between continuous variables (peak viremia and challenge virus-
specific immune responses, i.e. total ELISPOTs and IC90 titers)
were assessed using Spearman correlation analysis. Comparison of
the number of animals infected between vaccinees vs. controls was
assessed using the Fisher’s exact test. The reported P-values are
based on two-sided testing, unless specified otherwise.
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Figure S1 Phylogenetic analysis of Gag sequences of immuno-
gen and challenge virus. The Gag sequences of SIV and reference
HIV strains were obtained from Los Alamos HIV sequence
database. The evolutionary tree was inferred using the Neighbor-
Joining method by MEGA4 software. The immunogen and
challenge virus sequences are labeled with filled black circle.
(TIF)
Figure S2 All vaccinated (Group 1+ 2 RM) animals vs. Group 3
(control) RM. Kaplan-Meier plots depicting the fraction of RM
remaining aviremic (A) or not yet having reached peak viremia (B)
after low-dose SHIV-1157ipEL-p challenges. P values were
determined by 2-sided log rank analysis.
(TIF)
Figure S3 In vitro SHIV-1157ipEL-p replication in the PBMC
of protected animals. PBMC of the protected animals (RRi-11,
RTr-11, RGe-11), collected 4 weeks after high-dose virus
challenge were stimulated with concanavalin A (5 mg/ml) in the
presence of IL-2 (10 U/ml); 2610
6 unfractionated PBMC (A) or
CD8
+ cell-depleted PBMC (B) were exposed to SHIV-1157ipEL-p
(1610
4 TCID50). Virus replication was monitored by p27 ELISA
of culture supernatants. As control, virus replication in PBMC of a
naı ¨ve RM was also measured. Suppression of ex-vivo HIV-1
replication in cultured CD4
+ T cells by autologous CD8
+ T cells
from HIV-1-infected non-progressors has been reported [49].
Similarly, inhibition of ex-vivo SIV replication in cultured
macrophages by MHC- matched Gag- and Nef-specific CD4
+ T
cells from SIV-infected rhesus macaques has been reported [50].
(TIF)
Table S1 Viral RNA copies before and after ultracentrifugation.
Ten ml of plasma from monkeys RRi-11, RTr-11, and RGe-11
collected 4 weeks after high-dose SHIV-1157ipEL-p rechallenge
were ultracentrifuged (140,0006g for 5 h at 4uC) and the pellets
resuspended in 150 ml of PBS.
1RFa-10 was a chronically infected
RM with SHIV-1157ipEL-p from another study.
(PPT)
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